HOME >> MEDICINE >> NEWS
New compound unusually potent at blocking brain cancer growth

By determining how a class of compounds blocks signaling in cells, UCSF scientists have identified what is perhaps the most potent drug candidate yet against a highly lethal kind of brain tumor.

The compound, known as PI-103, shows unique potency against cancer cell proliferation in studies of mice with grafts of human glioma cells. Gliomas are the most common form of brain cancer, and have proven very difficult to treat.

The unique effectiveness of PI-103 stems from its ability to attack two separate steps in the series of signals that trigger the spread of cancer. The dual blockade proved to be a safe and effective inhibitor of cancer cell proliferation in mice with the human tumors, the scientists found.

The glioma research is being published online May 15 by the journal Cancer Cell. A description of the strategy used to identify the molecular level action of the inhibitors was published online by the journal Cell on April 27.

Food and Drug Administration approval five years ago of the cancer drug Gleevec marked a promising new strategy against cancer. Gleevec was the first drug on the market designed to block ubiquitous signaling molecules called protein kinases enzymes known to trigger normal cell proliferation, and in the case of cancer, the growth of tumors. Another group of kinases, called lipid kinases are now emerging as important new targets, especially PI3 alpha kinase, an enzyme often found to be overactive in brain, breast, colon and stomach cancers.

But the sheer number of related kinases 15 in the PI3 kinase family alone and uncertainty about how each acts in the body has stalled progress. Broad spectrum drugs that inhibit many related kinases inevitably cause toxicity and are poor drug candidates.

To overcome this hurdle, Kevan Shokat, PhD, a Howard Hughes Medical Institute investigator at UCSF, and Zachary Knight, a postdoctoral fellow in his lab, developed a strategy to systematically inhibit many different but r
'"/>

Contact: Wallace Ravven
wravven@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
15-May-2006


Page: 1 2 3

Related medicine news :

1. New oxidation methods streamline synthesis of important compounds
2. AMPAKINE compounds a new potential treatment for respiratory depression
3. Green tea compound suppresses factors causing cartilage, bone destruction in arthritis
4. Green tea compound may be a therapy for people with rheumatoid arthritis
5. Anti-dandruff compound may help fight epilepsy
6. Depression among retired NFL players: Rates mirror the general public, but pain compounds symptoms
7. Chromium 6: A killer compound with an improbable trigger
8. New compound shows promise in halting HIV spread
9. New imaging compound might see Alzheimers earlier
10. U of M researchers discover compounds to shrink tumors
11. Diagnosis and treatment of osteoporosis falls shortnon adherence compounds issue

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New compound unusually potent blocking brain cancer growth

(Date:7/28/2015)... ... 2015 , ... American Sentinel University has been named an ... Geisinger Health System (GHS), one of the nation’s largest integrated health services organizations. ... access to American Sentinel’s affordable, flexible and CCNE-accredited RN to BSN nursing degree ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... Education courses throughout California in the fall of 2015 . These seventeen ... Occupational Therapists. , Optimizing Functional Mobility in the Older Adult , ...
(Date:7/28/2015)... ... 28, 2015 , ... Peter Forbes, President of the Veterans Fund of the United States, managing ... the Veterans Coalition, is spearheading a campaign to help homeless Veterans by giving them “A ... and trade skills. Forbes and the UVBH assists and supports Vets through the Veterans ...
(Date:7/27/2015)... (PRWEB) , ... July 28, 2015 , ... Combination Product ... p.m. – 3:00 p.m. EDT, http:// http://www.fdanews.com/comboproductgmpcompliance , Manufacturing a ... makers of combination products things can get messy in a hurry. In a 46-page ...
(Date:7/27/2015)... ... ... The National Association of Professional Women (NAPW) honors Deana ... Circle. She is recognized with this prestigious distinction for leadership in healthcare. With more ... networking organization exclusively for professional women. , “I’m pleased to recognize Deana with this ...
Breaking Medicine News(10 mins):Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 2Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 3Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 4Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 2Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 3Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 4Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 5Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 6Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 7Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 8Health News:Veterans Fund of the United States Launches “Adopt A Homeless Veteran” Campaign 2Health News:Veterans Fund of the United States Launches “Adopt A Homeless Veteran” Campaign 3Health News:FDAnews Announces — Combination Product GMP Compliance: Understanding FDA’s New Streamline Approach Webinar, Aug. 19, 2015 2Health News:FDAnews Announces — Combination Product GMP Compliance: Understanding FDA’s New Streamline Approach Webinar, Aug. 19, 2015 3Health News:FDAnews Announces — Combination Product GMP Compliance: Understanding FDA’s New Streamline Approach Webinar, Aug. 19, 2015 4Health News:NAPW Inducts Deana Skidmore, Assistant Director of Nursing at Wilton Meadows Rehablilitation and Health Care Center, Into its VIP Woman of the Year Circle 2
(Date:7/27/2015)... CTI BioPharma Corp. (NASDAQ and MTA: CTIC) ... quarter 2015 financial results on Thursday, August 6, 2015, ... the announcement, members of the management team will host ... provide a general corporate update at 4:30 p.m. EDT ... obtained as follows: Thursday, August 6 1:30 ...
(Date:7/27/2015)... and PARIS , July ...  and Sanofi have entered into a new global ... treatments in the emerging field of immuno-oncology. As part ... a programmed cell death protein 1 (PD-1) inhibitor currently ... trials in 2016 with new therapeutic candidates based on ...
(Date:7/27/2015)... and WESTLAKE VILLAGE, Calif. ... AGN ) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: ... Commission (FTC) has granted early termination of the waiting ... (HSR Act) with respect to Allergan,s pending acquisition of ... On July 6, 2015, each of Allergan ...
Breaking Medicine Technology:CTI BioPharma to Report Second Quarter 2015 Financial Results on August 6, 2015 2Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 2Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 3Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 4Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 5Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 6Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 7Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 8Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 2Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 3Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 4Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 5Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 6Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 7Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 8Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 9
Cached News: